eprodisate

Trade name: Kiacta

Small moleculeexperimental

1,3-Propanedisulfonic acid is a sulfonic acid containing two sulfonate units. Its salts are called eprodisates and have been evaluated as a protector of renal function in AA amyloidosis. — Wikipedia

Clinical trial activity

3 trials · 3 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Oct 1, 2001 (NCT00035334)

Timeline

2000s

Jan 1, 2001
Earliest Phase 2 Sponsor(trial)

2010s

Jan 1, 2010
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Endoplasmic reticulum-associated amyloid beta-peptide-binding proteinINHIBITOR
HSD17B10 inhibitor
- 3-hydroxyacyl-CoA dehydrogenase type-2 (HSD17B10) ↗

Chemistry & pharmacology

Loading structure…

SMILES

O=S(=O)(O)CCCS(=O)(=O)O

Mol. weight: 204.22 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

eprodisate
eprodisate
eprodisate disodium
eprodisate disodium
eprodisate disodium
nc-503
nc-503
nc-503

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01215747	Phase 3	Nov 1, 2010	C.T. Development America, Inc.
NCT00675857	Phase 2	Apr 1, 2008	Bellus Health Inc
NCT00035334	Phase 2/Phase 3 (Phase 3)	Oct 1, 2001	Bellus Health Inc, Food and Drug Administration

Showing 3 of 3 trials

Page 1 / 1

Organizations

Research & Development (3)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Bellus Health Inc	For profit	2	2	2	2001
C.T. Development America, Inc.	For profit	1	1	1	2010
Food and Drug Administration	Government	1	0	1	2001

3 organizations

Page 1 / 1